Vietnam’s pharmaceutical market is expected to have a year of optimism after experiencing a multicoloured gamut in 2024.

and to work with like-minded suppliers. One way to ensure that Novo Nordisk’s approach to sustainability is carried through all parts of the business has been the way it has approached educating ...

Turkey's growing power pollution a sign of things to come February 6, 2025 Novo Nordisk emissions grew 23 ... Norway's Hoegh maps out hydrogen delivery plans to Germany February 5, 2025 Norway's ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Novo Nordisk's U.S.-listed shares are rising 4% in premarket trading after the Ozempic and Wegovy maker's better-than-estimated quarterly results offset slower 2025 sales growth projections amid ...

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid ...

Wegovy® is undoubtedly Novo Nordisk's biggest growth driver because it capitalizes on the population's poor health habits. Junk food, sedentary work, and lack of stimulation are all factors that ...

Novo Nordisk (NVO) CEO Lars Jørgensen isn't too worried about the upcoming Medicare price negotiations over blockbuster GLP-1 drugs, even though the company still stands with the industry against ...

While Novo’s type 2 diabetes GLP-1 Ozempic has largely stolen the show in recent years, obesity med Wegovy—which utilizes the same molecule semaglutide at higher doses than Ozempic ...

Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t its wildly popular weight-loss drugs. Novo Nordisk said its fourth ...